Placental protein 14 (PP14) does not predict endometrial status under hormone replacement therapy

Gynecological Endocrinology

Volumn 11, Issue 1, 1997, Pages 51-57

  Haenggi, W ^a,b   Bersinger, N A ^a   Altermatt, H J ^a   Birkhaeuser, M H ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Universitats Frauenklinik   (Switzerland)

Author keywords

17 estradiol; Dydrogesterone; Endometrium; Hormone replacement therapy; Menopause; Placental protein 14; Tibolone

Indexed keywords

DYDROGESTERONE; ESTRADIOL; PLACENTA PROTEIN 14; TIBOLONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG SAFETY; ENDOMETRIUM; ENZYME IMMUNOASSAY; FEMALE; HISTOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYSTERECTOMY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0031050947     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513599709152317     Document Type: Article

References (38)

1. Campbell, S. and White-head, M. (1977). Oestrogen therapy and the menopausal syndrome. Clin. Obstet. Gynecol., 4, 31-47
2. Fantl, J. A., Cardozo, L. and McClish, D. K. (1994). Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the hormones and urogenital therapy committee. Obstet. Gynecol., 83, 12-18
3. Lindsay, R., Hart, D. M. and Clark, D. M. (1984). The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet. Gynecol, 63, 759-63
4. Stampfer, M. J. and Colditz, G. A. (1991). Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev. Med., 20, 47-63
5. Ziel, H. K. and Finkle, W. D. (1975). Increased risk of endometrial carcinoma among users of conjugated estrogens. N. Engl. J. Med., 293, 1167-70
6. Smith, D. C., Prentice, R., Thompson, D. J. and Herman, W. L. (1975). Association of exogenous estrogen and endometrial carcinoma. N. Engl. J. Med., 293, 1164-7
7. Gambrell, R. D. Jr (1986). Prevention of endometrial cancer with progestogens. Maturitas, 8, 159-68
8. Fraser, I. S. (1986). A review of the role of progestogens in hormonal replacement therapy: influence on bleeding patterns. Maturitas, 8, 113-21
9. Padwick, M. L., Pryse-Davies, J. and Whitehead, M. I. (1986). A simple method for determining the optimal dose of progestin in postmenopausal women receiving estrogens. N. Engl. J. Med., 315, 930-4
10. Bell, S. C. (1988). Secretory endometrial/decidual proteins and their function in early pregnancy. J. Reprod. Fertil., 36 (Suppl.), 109-25
11. Bell, S. C. (1988). Synthesis and secretion of proteins by the endometrium and decidua. In Chapman, M., Grudzinskas, J. G. and Chard, T. (eds.) Implantation: Biological and Clinical Aspects. (London: Springer)
12. Johnson, M. R., Brooks, A., Norman-Taylor, J. Q., Grudzinskas, J. G., Wren, M. E., Murugni, P., Chard, T. and Abdalla, H. (1993). Serum placental protein 14 concentrations in the first trimester of ovum donation pregnancies. Hum. Reprod., 8, 485-7
13. Bersinger, N. A., Brandenberger, A. W., Zakher, A., Dreher, E., Altermatt, H. J. and Birkhaeuser, M. H. (1995). Production of endometrial placental protein 14 (PP14) and prolactin by cultured endometrial expiants after collagenase and freeze/thaw treatment, and in response to progesterone. Early Preg. Biol. Med., 1, 134-40
14. Haenggi, W., Riesen, W. and Birkhaeuser, M. H. (1993). Postmenopausal hormone replacement therapy with Tibolone decreases serum lipoprotein(a). Eur. J. Clin. Chem. Clin. Biochem., 31, 645-50
15. Haenggi, W., Linder, H. R., Birkhaeuser, M. H. and Schneider, H. (1995). Microscopic findings of the nail-fold capillaries - dependence on menopausal status and hormone replacement therapy. Maturitas, 22, 37-46
16. Bersinger, N. A., Brandenberger, A. W. and Birkhaeuser, M. H. (1995). Endometrial and placental protein markers and ovarian steroids in serum during in-vitro fertilisation cycles. Hum. Reprod., 10, 2149-54
17. Riittinen, L., Närvänen, O., Virtanen, I. and Seppälä, M. (1991). Monoclonal antibodies against endometrial protein PP14 and their use for purification and radioimmunoassay of PP14. J. Immunol. Meth., 136, 85-90
18. Cornier, E. (1984). The Pipelle: a disposable device for endometrial biopsy. Am. J. Obstet. Gynecol., 148, 109-10
19. Byrjalsen, I., Thormann, L., Meinecke, B., Riis, B. J. and Christiansen, C. (1992). Serum placental protein 14 (PP14) reflects endometrial status during hormone replacement therapy. Hum. Reprod., 7, 1042-7
20. Byrjalsen, I., Thormann, L., Riis, B. J. and Christiansen, C. (1992). Secretory endometrial protein PP14 in serum from post-menopausal women receiving continuous combined oestradiol-cyproterone acetate: correlation with serum hormone concentrations and bleeding patterns. Maturitas, 15, 39-46
21. Seppälä, M., Alfthan, H., Vartiainen, E., and Stenman, U. H. (1987). The post-menopausal uterus: the effect of hormone replacement therapy on serum levels of secretory endometrial protein PP14/β-lactoglobulin homologue. Hum. Reprod., 2, 741-3
22. Julkunen, M., Wahlström, T. and Seppälä, M. (1986). Human Fallopian tube contains placental protein 14. Am. J. Obstet. Gynecol., 154, 1076-9
23. Maguiness, S. D., Shrimanker, K., Djahanbakhch, O., Decks, J. J., Teisner, B. and Grudzinskas, J. G. (1993). In-vitro synthesis of total protein and placental protein PP14 by the Fallopian tube mucosa: variation in relation to anatomical site, the ovarian cycle and the menopause. Hum. Reprod., 8, 678-83
24. Riittinen, L. (1992). Serous ovarian cyst fluids contain high levels of endometrial placental protein 14. Tumour Biol, 13, 175-9
25. Telimaa, S., Kauppila, A., Rönnberg, L., Suikkari, A. M. and Seppälä, M. (1989). Elevated serum levels of endometrial secretory protein PP14 in patients with advanced endometriosis. Am. J. Obstet. Gynecol., 161, 866-71
26. Kamarainen, M., Riittinen, L., Seppälä, M., Palotie, A. and Andersson, L. C. (1994). Progesterone- associated endometrial protein - a constitutive marker of human erythroid precursors. Blood, 84, 467-73
27. Siddle, N. C., Jesinger, D. K., Whitehead, M. I., Turner, P., Lewis, B. and Prescott, P. (1990). Effect on plasma lipids and lipoproteins of postmenopausal oestrogen therapy with added dydrogesterone. Br. J. Obstet. Gynaecol., 97, 1093-100
28. Vermorken, A. J., Sultan, C. and Goos, C. M. (1987). Dydrogesterone has no peripheral (anti)-androgenic properties. In Vivo, 1, 167-71
29. Greenwood, P. A. and Jesinger, D. K. (1991). Dydrogesterone to oppose the 100 mg oestradiol implant. Maturitas, 14, 17-21
30. Rees, M., Leather, A., Pryse-Davies, J., Collins, S. A., Barlow, D. H. and Studd, J. W. (1991). A first study to compare two dosages of dydrogesterone in opposing the 50 mg oestradiol implant. Maturitas, 14, 9-15
31. Siddle, N. C., Fraser, D., Whitehead, M. I., Jesinger, D. K., Endacott, J., Prescott, P. and Pryse-Davies, J. (1990). Endometrial, physical and psychological effects of postmenopausal oestrogen therapy with added dydrogesterone. Br. J. Obstet. Gynaecol., 97, 1101-7
32. Lane, G., Siddle, N. C., Ryder, T. A., Pryse-Davies, J., King, R. J. and Whitehead, M. (1986). Effects of dydrogesterone on the oestrogenized postmenopausal endometrium. Br. J. Obstet. Gynaecol, 93, 55-62
33. De Visser, J., Coert, A., Feenstra, H. and van der Vies, J. (1984). Endocrinological studies with (7α, 17α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14). Arzneimittel-forschung, 34, 1010-17
34. Benedek Jaszmann, L. J. (1987). Long-term placebo-controlled efficacy and safety study of Org OD 14 in climacteric women. Maturitas (Suppl. 1), 25-33
35. Lindsay, R., Hart, D. M. and Kraszewski, A. (1980). A prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br. Med. J., 280, 1207-9
36. Genazzani, A. R., Benedek Jaszmann, L. J., Hart, D. M., Andolsek, L., Kicovic, P. M. and Tax, L. (1991). Org OD 14 and the endometrium. Maturitas, 13, 243-51
37. Rymer, J., Fogelman, I. and Chapman, M. G. (1994). The incidence of vaginal bleeding with tibolone treatment. Br. J. Obstet. Gynaecol., 101, 53-6
38. Ren, S. G., Braunstein, G. D., Cedars, M., Gambone, J. and Judd, H. (1990). Serum concentrations of two endometrial proteins are not useful for monitoring postmenopausal estrogen/ progesterone therapy. Fertil. Steril., 54, 532-4